Carbon  ||| S:0 E:7 ||| NN
dioxide  ||| S:7 E:15 ||| NN
laser  ||| S:15 E:21 ||| NN
plus  ||| S:21 E:26 ||| CC
topical  ||| S:26 E:34 ||| JJ
5-fluorouracil ||| S:34 E:48 ||| NN
:  ||| S:48 E:50 ||| :
a  ||| S:50 E:52 ||| DT
new  ||| S:52 E:56 ||| JJ
combination  ||| S:56 E:68 ||| NN
therapeutic  ||| S:68 E:80 ||| JJ
modality  ||| S:80 E:89 ||| NN
for  ||| S:89 E:93 ||| IN
acral  ||| S:93 E:99 ||| FW
vitiligo  ||| S:99 E:108 ||| FW
Acral  ||| S:108 E:114 ||| FW
vitiligo  ||| S:114 E:123 ||| FW
( ||| S:123 E:124 ||| -LRB-
AV ||| S:124 E:126 ||| NNP
)  ||| S:126 E:128 ||| -RRB-
is  ||| S:128 E:131 ||| VBZ
resistant  ||| S:131 E:141 ||| VBN
to  ||| S:141 E:144 ||| TO
treatment ||| S:144 E:153 ||| NN
.  ||| S:153 E:155 ||| .
To  ||| S:155 E:158 ||| TO
evaluate  ||| S:158 E:167 ||| VB
efficacy  ||| S:167 E:176 ||| NNS
and  ||| S:176 E:180 ||| CC
safety  ||| S:180 E:187 ||| NN
of  ||| S:187 E:190 ||| IN
combining  ||| S:190 E:200 ||| VBG
carbon  ||| S:200 E:207 ||| NN
dioxide  ||| S:207 E:215 ||| NN
( ||| S:215 E:216 ||| -LRB-
CO2 ||| S:216 E:219 ||| NNP
)  ||| S:219 E:221 ||| -RRB-
laser  ||| S:221 E:227 ||| NN
and  ||| S:227 E:231 ||| CC
5-fluorouracil  ||| S:231 E:246 ||| NN
( ||| S:246 E:247 ||| -LRB-
5FU ||| S:247 E:250 ||| NNP
)  ||| S:250 E:252 ||| -RRB-
in  ||| S:252 E:255 ||| IN
treating  ||| S:255 E:264 ||| VBG
AV ||| S:264 E:266 ||| NNP
.  ||| S:266 E:268 ||| .
This  ||| S:268 E:273 ||| DT
study  ||| S:273 E:279 ||| NN
included  ||| S:279 E:288 ||| VBD
68  ||| S:288 E:291 ||| CD
adult  ||| S:291 E:297 ||| NN
patients  ||| S:297 E:306 ||| NNS
with  ||| S:306 E:311 ||| IN
AV ||| S:311 E:313 ||| NNP
.  ||| S:313 E:315 ||| .
After  ||| S:315 E:321 ||| IN
randomly  ||| S:321 E:330 ||| RB
assigning  ||| S:330 E:340 ||| JJ
patients  ||| S:340 E:349 ||| NNS
into  ||| S:349 E:354 ||| IN
3  ||| S:354 E:356 ||| CD
groups ||| S:356 E:362 ||| NNS
,  ||| S:362 E:364 ||| ,
patients  ||| S:364 E:373 ||| NNS
in  ||| S:373 E:376 ||| IN
group  ||| S:376 E:382 ||| NN
I  ||| S:382 E:384 ||| PRP
were  ||| S:384 E:389 ||| VBD
treated  ||| S:389 E:397 ||| VBN
using  ||| S:397 E:403 ||| VBG
5FU ||| S:403 E:406 ||| NNP
,  ||| S:406 E:408 ||| ,
group  ||| S:408 E:414 ||| NN
II  ||| S:414 E:417 ||| NNP
were  ||| S:417 E:422 ||| VBD
treated  ||| S:422 E:430 ||| VBN
using  ||| S:430 E:436 ||| VBG
CO2  ||| S:436 E:440 ||| CD
laser ||| S:440 E:445 ||| NN
,  ||| S:445 E:447 ||| ,
and  ||| S:447 E:451 ||| CC
group  ||| S:451 E:457 ||| NN
III  ||| S:457 E:461 ||| NNP
were  ||| S:461 E:466 ||| VBD
treated  ||| S:466 E:474 ||| VBN
using  ||| S:474 E:480 ||| VBG
CO2  ||| S:480 E:484 ||| CD
laser  ||| S:484 E:490 ||| NN
followed  ||| S:490 E:499 ||| VBN
by  ||| S:499 E:502 ||| IN
5FU  ||| S:502 E:506 ||| CD
for  ||| S:506 E:510 ||| IN
a  ||| S:510 E:512 ||| DT
maximum  ||| S:512 E:520 ||| JJ
period  ||| S:520 E:527 ||| NN
of  ||| S:527 E:530 ||| IN
5  ||| S:530 E:532 ||| CD
months ||| S:532 E:538 ||| NNS
.  ||| S:538 E:540 ||| .
The  ||| S:540 E:544 ||| DT
lesions  ||| S:544 E:552 ||| NN
were  ||| S:552 E:557 ||| VBD
then  ||| S:557 E:562 ||| RB
evaluated  ||| S:562 E:572 ||| VBN
both  ||| S:572 E:577 ||| DT
qualitatively  ||| S:577 E:591 ||| NN
and  ||| S:591 E:595 ||| CC
quantitatively ||| S:595 E:609 ||| NN
.  ||| S:609 E:611 ||| .
Almost  ||| S:611 E:618 ||| RB
half  ||| S:618 E:623 ||| NN
( ||| S:623 E:624 ||| -LRB-
49.8 ||| S:624 E:628 ||| CD
% ||| S:628 E:629 ||| NN
)  ||| S:629 E:631 ||| -RRB-
of  ||| S:631 E:634 ||| IN
the  ||| S:634 E:638 ||| DT
lesions  ||| S:638 E:646 ||| NN
in  ||| S:646 E:649 ||| IN
group  ||| S:649 E:655 ||| NN
III  ||| S:655 E:659 ||| NNP
achieved  ||| S:659 E:668 ||| VBD
G4 ||| S:668 E:670 ||| CD
,  ||| S:670 E:672 ||| ,
and  ||| S:672 E:676 ||| CC
6.1 ||| S:676 E:679 ||| CD
%  ||| S:679 E:681 ||| NN
of  ||| S:681 E:684 ||| IN
lesions  ||| S:684 E:692 ||| NNS
achieved  ||| S:692 E:701 ||| VBD
G3  ||| S:701 E:704 ||| CD
re-pigmentation ||| S:704 E:719 ||| NN
.  ||| S:719 E:721 ||| .
This  ||| S:721 E:726 ||| DT
response  ||| S:726 E:735 ||| NN
was  ||| S:735 E:739 ||| VBD
statistically  ||| S:739 E:753 ||| RB
significantly  ||| S:753 E:767 ||| RB
higher  ||| S:767 E:774 ||| JJR
than  ||| S:774 E:779 ||| IN
that  ||| S:779 E:784 ||| DT
in  ||| S:784 E:787 ||| IN
the  ||| S:787 E:791 ||| DT
other  ||| S:791 E:797 ||| JJ
two  ||| S:797 E:801 ||| CD
groups ||| S:801 E:807 ||| NNS
.  ||| S:807 E:809 ||| .
This  ||| S:809 E:814 ||| DT
was  ||| S:814 E:818 ||| VBD
not  ||| S:818 E:822 ||| RB
achieved  ||| S:822 E:831 ||| VBN
in  ||| S:831 E:834 ||| IN
periungual  ||| S:834 E:845 ||| JJ
areas  ||| S:845 E:851 ||| NNS
in  ||| S:851 E:854 ||| IN
the  ||| S:854 E:858 ||| DT
hands  ||| S:858 E:864 ||| NNS
and  ||| S:864 E:868 ||| CC
feet ||| S:868 E:872 ||| NNS
.  ||| S:872 E:874 ||| .
The  ||| S:874 E:878 ||| DT
pain  ||| S:878 E:883 ||| NN
was  ||| S:883 E:887 ||| VBD
tolerable  ||| S:887 E:897 ||| VBN
during  ||| S:897 E:904 ||| IN
sessions  ||| S:904 E:913 ||| NNS
or  ||| S:913 E:916 ||| CC
at  ||| S:916 E:919 ||| IN
sites  ||| S:919 E:925 ||| NNS
of  ||| S:925 E:928 ||| IN
5FU  ||| S:928 E:932 ||| CD
application ||| S:932 E:943 ||| NN
.  ||| S:943 E:945 ||| .
Transient  ||| S:945 E:955 ||| JJ
hyperpigmentation ||| S:955 E:972 ||| NN
,  ||| S:972 E:974 ||| ,
brownish  ||| S:974 E:983 ||| JJ
spot  ||| S:983 E:988 ||| NN
on  ||| S:988 E:991 ||| IN
nail  ||| S:991 E:996 ||| JJ
plates ||| S:996 E:1002 ||| NN
,  ||| S:1002 E:1004 ||| ,
itching ||| S:1004 E:1011 ||| NN
,  ||| S:1011 E:1013 ||| ,
and  ||| S:1013 E:1017 ||| CC
infection  ||| S:1017 E:1027 ||| NN
were  ||| S:1027 E:1032 ||| VBD
temporary  ||| S:1032 E:1042 ||| JJ
side  ||| S:1042 E:1047 ||| NN
effects ||| S:1047 E:1054 ||| NNS
;  ||| S:1054 E:1056 ||| :
however ||| S:1056 E:1063 ||| RB
,  ||| S:1063 E:1065 ||| ,
Koebnerization  ||| S:1065 E:1080 ||| NNP
was  ||| S:1080 E:1084 ||| VBD
not  ||| S:1084 E:1088 ||| RB
detected ||| S:1088 E:1096 ||| VBN
.  ||| S:1096 E:1098 ||| .
We  ||| S:1098 E:1101 ||| PRP
concluded  ||| S:1101 E:1111 ||| VBD
that  ||| S:1111 E:1116 ||| DT
prior  ||| S:1116 E:1122 ||| JJ
use  ||| S:1122 E:1126 ||| NN
of  ||| S:1126 E:1129 ||| IN
CO2  ||| S:1129 E:1133 ||| CD
laser  ||| S:1133 E:1139 ||| NN
skin  ||| S:1139 E:1144 ||| NN
ablation ||| S:1144 E:1152 ||| NN
,  ||| S:1152 E:1154 ||| ,
followed  ||| S:1154 E:1163 ||| VBN
by  ||| S:1163 E:1166 ||| IN
5FU  ||| S:1166 E:1170 ||| CD
application  ||| S:1170 E:1182 ||| NN
for  ||| S:1182 E:1186 ||| IN
AV  ||| S:1186 E:1189 ||| NNP
is  ||| S:1189 E:1192 ||| VBZ
a  ||| S:1192 E:1194 ||| DT
safe  ||| S:1194 E:1199 ||| JJ
and  ||| S:1199 E:1203 ||| CC
tolerable  ||| S:1203 E:1213 ||| JJ
technique  ||| S:1213 E:1223 ||| NN
that  ||| S:1223 E:1228 ||| WDT
improves  ||| S:1228 E:1237 ||| VBZ
the  ||| S:1237 E:1241 ||| DT
outcome  ||| S:1241 E:1249 ||| NN
and  ||| S:1249 E:1253 ||| CC
increases  ||| S:1253 E:1263 ||| NNS
patient  ||| S:1263 E:1271 ||| JJ
compliance ||| S:1271 E:1281 ||| NN
.  ||| S:1281 E:1283 ||| .
